Reading room

Peptide medicines & new families.

Explore how defined peptide medicines work in specific clinical settings, from melanocortin signaling and amylin to GLP-2, local gut receptors and bone biology. Keep molecular identity, formulation, indications and measured outcomes together.

Reset filters

Guides in this topic

13–19 of 19 guides

Page 2 of 2
Old somatostatin-reference envelope above two physically different formulation-study files Octreotide and Lanreotide, in the Octreotide vs Lanreotide research file.Peptide Fundamentals

Lanreotide vs Octreotide: Formulations and Trial Evidence

Compare lanreotide and octreotide by formulation, half-life and trial endpoint. PROMID and CLARINET tested each medicine against placebo, rather than against each other.

Updated 2026-11-05 ↗
Complement-system research assay tray with a single C3 specimen identity tab and independent clinical-context archive sleeves, in the Pegcetacoplan research file.Peptide Fundamentals

Pegcetacoplan: C3 Inhibition Across Different Clinical Contexts

Pegcetacoplan binds complement C3 and C3b, but that target description does not make its different clinical settings equivalent.

Updated 2026-10-29 ↗
Amylin research index slip and a gastric-function teaching specimen with an independent Pramlintide study folder.Peptide Fundamentals

Pramlintide: Understanding Amylin Beyond the GLP-1 Headlines

Pramlintide is an amylin analogue with a product-specific role alongside mealtime insulin. Its evidence should not be read as a generic weight-loss-peptide comparison.

Updated 2026-10-29 ↗
Setmelanotide dossier with an MC4 signaling index card, genetics references and a clinical eligibility file.Peptide Fundamentals

Setmelanotide: MC4 Signaling and Specific Obesity Conditions

Setmelanotide is an MC4-receptor agonist with a clinical record tied to specified causes and contexts of obesity.

Updated 2026-10-29 ↗
short-bowel teaching specimen and an archived support-requirements file, in the Teduglutide and GLP-2 research file.Peptide Fundamentals

Teduglutide and GLP-2: Evidence in Short Bowel Syndrome

Teduglutide is a GLP-2 analogue whose clinical record concerns short bowel syndrome with dependence on parenteral support.

Updated 2026-10-29 ↗
long-bone end teaching specimen and an enlarged cartilage growth-plate model in a pale padded specimen box, in the Vosoritide research file.Peptide Fundamentals

Vosoritide: CNP Signaling, Growth Velocity and Achondroplasia

Vosoritide is a C-type natriuretic peptide analogue studied for achondroplasia. Its evidence concerns growth-plate biology and growth velocity in an eligible pediatric population, not a general height-enhancement claim.

Updated 2026-10-29 ↗
natural cone-snail shell preserved in a conservation box beside a resin neuron teaching specimen, in the Ziconotide research file.Peptide Fundamentals

Ziconotide: A Conopeptide with a Very Specific Clinical Role

Ziconotide is a conopeptide medicine with a highly specific pain-management setting and route. Its N-type calcium-channel binding helps explain the research rationale, but the product record also contains substantial safety restrictions.

Updated 2026-10-29 ↗

Explore the related peptide dossiers

Peptide Medicines & Emerging Research Families: Page 2 | PeptideTwo